Company: DVAX
Filing Date: 2025-04-17
Form Type: PRRN14A
Source: 0001193125-25-084044
Chunk: 14

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-04-17
Form: PRRN14A
Chunk 14
---
 an experienced perspective to the Board on issues relating to finance.

Michael Mullette, age 45.

Michael Mullette is an experienced drug development and commercialization professional with decades of experience growing
businesses. Mr. Mullette has most recently been serving as interim CEO of Lykos Therapeutics since September 2024 and Chief Operating Officer since March of 2022. Before that, Mr. Mullette served as vice president of North America
commercial operations for Moderna from July 2020 to March 2022, where he oversaw commercialization of the company’s COVID-19 vaccine during the height of the
COVID-19 pandemic. Before Moderna he spent almost 20 years with Sanofi Pasteur working in vaccine, commercial, business development, operations, strategy, planning, marketing and sales in roles of increasing
levels of responsibility in the US, France, Australia, Japan, and Canada. Mike earned his Bachelor of Business Administration from Villanova University and an M.B.A. from Lehigh University.

As an interim chief executive officer, chief operating officer, and executive in the healthcare industry, Mr. Mullette provides insight
into operational matters, along with industry knowledge and experience in healthcare and pharmaceuticals. Mr. Mullette would bring to the Company strong leadership and day-to- day operational experience,
and a deep understanding of business risks, based on his leadership positions in the healthcare and biotechnology space.

Donald Santel, age 64.

Donald Santel currently serves as chairman of the board of a private biotechnology company, Tentarix Biotherapeutics, since March
2022, as an independent director of private biotechnology company, Inograft

16

Biotherapeutics, since December 2023 and independent director of private biotechnology company, March Therapeutics, since August 2024. Since January 2023, he has served on the board of Aerovate
Therapeutics, a public biotechnology company (NASDAQ: AVTE). Mr. Santel previously served on the board of directors of Oyster Point Pharma, Inc., a publicly-traded commercial-stage biopharmaceutical company focused on therapies to treat ophthalmic
diseases, from August 2021 until the sale of the company to Viatris, Inc. in January 2023. Mr. Santel served on the board of Consonance-HFW Acquisition Corp. from December 2020 to August 2021. Mr. Santel also previously served as Executive
Chairman of Adicet Bio